New drug combo offers hope for deadly thyroid cancer
NCT ID NCT06374602
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 31 times
Summary
This study tests two drugs, pembrolizumab and lenvatinib, in 20 people with anaplastic thyroid cancer, a rare and fast-growing cancer. The goal is to see if the combination can shrink tumors and help people live longer. Participants must be 18 or older and have not had prior treatment with certain targeted therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint Petersburg State University Hospital
RECRUITINGSaint Petersburg, 190020, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.